Biocon Biologics signs distribution partnership with Sandoz for Adalimumab BS Subcutaneous Injection in Japan

The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio

Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug

Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya

Biocon Biologics completes Integration of Viatris' Biosimilar business

The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million

Zydus appoints Punit Patel as President and CEO, Americas

Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace

Amgen settles with FTC over US$28 billion deal

Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products

ABB India bags automation order for Reliance Life Sciences' biopharmaceutical facilities

ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra

Biocon Biologics announces leadership appointments

Sandoz plans to build a Biosimilar Technical Development Center in Slovenia

Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026

Biocon Biologics expands footprint in emerging markets

Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries